Multicenter phase II study of S-1 and docetaxel combination chemotherapy for advanced or recurrent gastric cancer patients with peritoneal dissemination

Kunitoshi Shigeyasu, Shunsuke Kagawa, Futoshi Uno, Masahiko Nishizaki, Hiroyuki Kishimoto, Akira Gochi, Toshikazu Kimura, Takaomi Takahata, Yasuyuki Nonaka, Motoki Ninomiya, Toshiyoshi Fujiwara

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose: Peritoneal dissemination is the most frequent and life-threatening mode of metastasis and recurrence in patients with gastric cancer. A multicenter phase II study was designed to evaluate the efficacy and tolerability of S-1 and docetaxel combination chemotherapy regimen for the treatment of advanced or recurrent gastric cancer patients with peritoneal dissemination. Methods: Nineteen patients with histologically confirmed unresectable or recurrent gastric cancer with peritoneal dissemination were enrolled. Oral S-1 at 80 mg/m2/day was administered twice daily for 2 weeks, followed by 1 drug-free week. Docetaxel infusion at 40 mg/m2 was performed on day 1, simultaneous with S-1 administration. The primary endpoints were overall survival (OS) and time to progression (TTP). The secondary endpoints were the response rates and safety status. Results: Patients received a median of 4 cycles of the S-1 and docetaxel regimen (range 1-43). The disease control rate was 73.7 % (14/19). Median overall survival was 459 days (15.3 months), while median time to progression was 212 days (7.1 months). Neutropenia was the most common type of toxicity (n = 7, 36.8 %). Conclusions: Combination chemotherapy with S-1 and docetaxel is a tolerable and effective treatment for advanced or recurrent gastric cancer patients with peritoneal dissemination.

Original languageEnglish
Pages (from-to)937-943
Number of pages7
JournalCancer Chemotherapy and Pharmacology
Volume71
Issue number4
DOIs
Publication statusPublished - Apr 2013

Fingerprint

docetaxel
Chemotherapy
Combination Drug Therapy
Stomach Neoplasms
Disease control
Survival
Toxicity
Neutropenia
S 1 (combination)
Neoplasm Metastasis
Safety
Recurrence
Pharmaceutical Preparations

Keywords

  • Docetaxel
  • Gastric cancer
  • Peritoneal dissemination
  • Phase II study
  • S-1

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Toxicology

Cite this

Multicenter phase II study of S-1 and docetaxel combination chemotherapy for advanced or recurrent gastric cancer patients with peritoneal dissemination. / Shigeyasu, Kunitoshi; Kagawa, Shunsuke; Uno, Futoshi; Nishizaki, Masahiko; Kishimoto, Hiroyuki; Gochi, Akira; Kimura, Toshikazu; Takahata, Takaomi; Nonaka, Yasuyuki; Ninomiya, Motoki; Fujiwara, Toshiyoshi.

In: Cancer Chemotherapy and Pharmacology, Vol. 71, No. 4, 04.2013, p. 937-943.

Research output: Contribution to journalArticle

@article{51a06f0bbe924caba9194fea25d13779,
title = "Multicenter phase II study of S-1 and docetaxel combination chemotherapy for advanced or recurrent gastric cancer patients with peritoneal dissemination",
abstract = "Purpose: Peritoneal dissemination is the most frequent and life-threatening mode of metastasis and recurrence in patients with gastric cancer. A multicenter phase II study was designed to evaluate the efficacy and tolerability of S-1 and docetaxel combination chemotherapy regimen for the treatment of advanced or recurrent gastric cancer patients with peritoneal dissemination. Methods: Nineteen patients with histologically confirmed unresectable or recurrent gastric cancer with peritoneal dissemination were enrolled. Oral S-1 at 80 mg/m2/day was administered twice daily for 2 weeks, followed by 1 drug-free week. Docetaxel infusion at 40 mg/m2 was performed on day 1, simultaneous with S-1 administration. The primary endpoints were overall survival (OS) and time to progression (TTP). The secondary endpoints were the response rates and safety status. Results: Patients received a median of 4 cycles of the S-1 and docetaxel regimen (range 1-43). The disease control rate was 73.7 {\%} (14/19). Median overall survival was 459 days (15.3 months), while median time to progression was 212 days (7.1 months). Neutropenia was the most common type of toxicity (n = 7, 36.8 {\%}). Conclusions: Combination chemotherapy with S-1 and docetaxel is a tolerable and effective treatment for advanced or recurrent gastric cancer patients with peritoneal dissemination.",
keywords = "Docetaxel, Gastric cancer, Peritoneal dissemination, Phase II study, S-1",
author = "Kunitoshi Shigeyasu and Shunsuke Kagawa and Futoshi Uno and Masahiko Nishizaki and Hiroyuki Kishimoto and Akira Gochi and Toshikazu Kimura and Takaomi Takahata and Yasuyuki Nonaka and Motoki Ninomiya and Toshiyoshi Fujiwara",
year = "2013",
month = "4",
doi = "10.1007/s00280-013-2086-0",
language = "English",
volume = "71",
pages = "937--943",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Multicenter phase II study of S-1 and docetaxel combination chemotherapy for advanced or recurrent gastric cancer patients with peritoneal dissemination

AU - Shigeyasu, Kunitoshi

AU - Kagawa, Shunsuke

AU - Uno, Futoshi

AU - Nishizaki, Masahiko

AU - Kishimoto, Hiroyuki

AU - Gochi, Akira

AU - Kimura, Toshikazu

AU - Takahata, Takaomi

AU - Nonaka, Yasuyuki

AU - Ninomiya, Motoki

AU - Fujiwara, Toshiyoshi

PY - 2013/4

Y1 - 2013/4

N2 - Purpose: Peritoneal dissemination is the most frequent and life-threatening mode of metastasis and recurrence in patients with gastric cancer. A multicenter phase II study was designed to evaluate the efficacy and tolerability of S-1 and docetaxel combination chemotherapy regimen for the treatment of advanced or recurrent gastric cancer patients with peritoneal dissemination. Methods: Nineteen patients with histologically confirmed unresectable or recurrent gastric cancer with peritoneal dissemination were enrolled. Oral S-1 at 80 mg/m2/day was administered twice daily for 2 weeks, followed by 1 drug-free week. Docetaxel infusion at 40 mg/m2 was performed on day 1, simultaneous with S-1 administration. The primary endpoints were overall survival (OS) and time to progression (TTP). The secondary endpoints were the response rates and safety status. Results: Patients received a median of 4 cycles of the S-1 and docetaxel regimen (range 1-43). The disease control rate was 73.7 % (14/19). Median overall survival was 459 days (15.3 months), while median time to progression was 212 days (7.1 months). Neutropenia was the most common type of toxicity (n = 7, 36.8 %). Conclusions: Combination chemotherapy with S-1 and docetaxel is a tolerable and effective treatment for advanced or recurrent gastric cancer patients with peritoneal dissemination.

AB - Purpose: Peritoneal dissemination is the most frequent and life-threatening mode of metastasis and recurrence in patients with gastric cancer. A multicenter phase II study was designed to evaluate the efficacy and tolerability of S-1 and docetaxel combination chemotherapy regimen for the treatment of advanced or recurrent gastric cancer patients with peritoneal dissemination. Methods: Nineteen patients with histologically confirmed unresectable or recurrent gastric cancer with peritoneal dissemination were enrolled. Oral S-1 at 80 mg/m2/day was administered twice daily for 2 weeks, followed by 1 drug-free week. Docetaxel infusion at 40 mg/m2 was performed on day 1, simultaneous with S-1 administration. The primary endpoints were overall survival (OS) and time to progression (TTP). The secondary endpoints were the response rates and safety status. Results: Patients received a median of 4 cycles of the S-1 and docetaxel regimen (range 1-43). The disease control rate was 73.7 % (14/19). Median overall survival was 459 days (15.3 months), while median time to progression was 212 days (7.1 months). Neutropenia was the most common type of toxicity (n = 7, 36.8 %). Conclusions: Combination chemotherapy with S-1 and docetaxel is a tolerable and effective treatment for advanced or recurrent gastric cancer patients with peritoneal dissemination.

KW - Docetaxel

KW - Gastric cancer

KW - Peritoneal dissemination

KW - Phase II study

KW - S-1

UR - http://www.scopus.com/inward/record.url?scp=84878848410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878848410&partnerID=8YFLogxK

U2 - 10.1007/s00280-013-2086-0

DO - 10.1007/s00280-013-2086-0

M3 - Article

VL - 71

SP - 937

EP - 943

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 4

ER -